Stock data
| Market cap. | US$133.7m |
| Last close | US$2.85 |
| High / Low (52 weeks) | US$3.1 / US$1.1 |
| Stock market listing | NASDAQ |
| Forecast net cash (US$m) | 5.7 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (6.5574) | 57.4586 | 3.6363 |
| Relative * | (3.3996) | 61.4093 | 4.0017 |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 0.0 | (21.3) | (24.6) | (593.7) | N/A | N/A |
| 2011A | 5.0 | (25.8) | (20.1) | (43.3) | N/A | N/A |
| 2012E | 0.0 | (32.5) | (30.5) | (65.4) | N/A | N/A |
| 2013E | 0.0 | (32.5) | (32.9) | (70.5) | N/A | N/A |
Last updated on 19/04/2012
Latest research
He who would valiant be
Update | Pharmaceutical & Healthcare | 04/04/2012
Interim analysis in Q3
Update | Pharmaceutical & Healthcare | 19/03/2012
Large IST in AML/MDS
Update | Pharmaceutical & Healthcare | 16/12/2011
Vosaroxin gets safety OK
Update | Pharmaceutical & Healthcare | 12/12/2011
R&D update, loan facility
Review | Pharmaceutical & Healthcare | 26/10/2011
Bravely taking on AML
Outlook | Pharmaceutical & Healthcare | 13/10/2011
Investment summary
Sunesis is moving closer to its key 2012 event - the interim analysis of its pivotal VALOR Phase III study of vosaroxin in relapsed/refractory acute myeloid leukaemia. The 187-event trigger point for the interim analysis is now projected in Q3. The VALOR study has enrolled 260 patients to date and should reach full recruitment of 450 in Q4. Sunesis’s investment case rests entirely on the outcome of the VALOR study and so the interim analysis is of critical importance. Our revised model now indicates a valuation of $300m (of which AML contributes $270m). Sunesis offers a potentially highly geared upside linked to success in the VALOR study, albeit with a high single-product risk. A new $25m royalty funding deal should allow Sunesis to accelerate commercial plans for vosaroxin while extending its cash reach.
Last updated on 23/04/2012
Industry outlook
Of the range of alternative treatments for AML, Dacogen is the most advanced - Eisai/J&J received approval earlier this year for its NDA for the drug. Other programs will report in the near term, including a 300-patient Phase II study of Astellas's Quiztarnib.
Last updated on 23/04/2012
Key management
| James Young, Chairman |
| Daniel Swisher, CEO |
| Eric Bjerkholt, CFO |
Company address
| 395 Oyster Point Boulevard Suite 400 South San Francisco CA 94080 United States +1 (650) 266-3500 View website |
